At baseline, BCVA was slightly better in the bilateral neovascular AMD group (0.83 ± 0.49 LogMAR) than in the unilateral neovascular AMD group (0.90 ± 0.53 LogMAR), although this difference did not reach statistical significance ( p = 0.215).
← all excerpts
The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD.
1
0.2150
0.2150